INNOVATE Earnings Call Transcripts
Fiscal Year 2026
-
Directors and executive officers were introduced, and all four shareholder proposals—including director elections, executive compensation, equity plan amendment, and auditor ratification—were approved. No questions were submitted during the Q&A session.
-
Q1 2026 saw 33% revenue growth to $364.8M and improved adjusted EBITDA, driven by infrastructure gains, while Life Sciences and Spectrum faced revenue declines. Net loss narrowed, cash increased, and backlog remains strong, supporting a positive outlook.
Fiscal Year 2025
-
Fourth quarter revenue surged 61.7% year-over-year, driven by infrastructure, while net loss narrowed. Life sciences and spectrum segments faced headwinds, but regulatory wins and backlog growth position the company for 2026 expansion.
-
Q3 2025 revenue rose 43% year-over-year to $347.1M, led by infrastructure and life sciences growth, while net loss narrowed. DBM Global's backlog and R2's international sales surged, and MediBeacon secured key regulatory approval in China.
-
Q2 2025 saw a 22.7% revenue decline and a net loss of $22 million, driven by lower infrastructure and Spectrum results, partially offset by strong Life Sciences growth. Strategic refinancing extended debt maturities, while DBM Global and R2 maintained robust backlogs and positive outlooks.
-
Q1 2025 revenue fell 13% year-over-year to $274.2 million, with adjusted EBITDA at $7.2 million and a net loss of $24.8 million. Infrastructure backlog reached $1.4 billion, life sciences saw strong R2 growth, and Spectrum advanced new tech initiatives.
Fiscal Year 2024
-
Q4 2024 revenue fell 34.5% year-over-year to $236.6M, with adjusted EBITDA at $15M. Life sciences and Spectrum segments saw strong growth, while infrastructure faced project delays but maintained a robust backlog. Total debt was reduced by $54.5M year-over-year.
-
Q3 2024 revenue fell 35.5% year-over-year to $242.2M, with net loss widening to $15.3M. Life sciences and Spectrum segments posted strong growth, while infrastructure declined. Backlog and debt reduction position the company for 2025.
-
Q2 2024 saw $313.1M in revenue and $26.7M in Adjusted EBITDA, with strong margin expansion and robust growth in life sciences and Spectrum. Infrastructure backlog stabilized, and capital structure improvements are underway, including a reverse stock split.